Poor Sleep in Medicated Patients with Remitted Depressive Disorder: A Naturalistic Study

10.4103/TPSY.TPSY_10_20

Tsung-Hua Lu；Po See Chen；Kao Chin Chen；I Hui Lee；Yen Kuang Yang

depression ； remission ； residual symptoms ； sleep

台灣精神醫學

34卷1期（2020 / 03 / 01）

42 - 46

英文

Objectives: Depression with partial remission and residual symptoms following treatments is common. Elucidating the problems remaining in the remitted patients would help optimize treatment. In this study, we intended to study remission rate and related factors as well as their unresolved problems in patients with treated depressive disorder. Methods: We included 65 medicated patients with depression for 6-12 months. We also chose 65 healthy persons as a control group. The study participants completed Beck Depression Inventory (BDI), checklists of side effects, Sheehan Disability Scale, World Health Organization Quality-of-Life-brief version, and Pittsburgh Sleep Quality Index (PSQI). Remission was defined as a BDI score of ≤ 15. Results: We found that the PSQI score was still higher in the remission group than the control group. Conclusion: Sleep problems, which may still be a commonly unresolved problem in medicated patients with depression, should be noticed by clinicians.

1. Beck, AT,Steer, RA,Brown, GK(1996).BDI-II: Beck Depression Inventory Manual.New York City:Harcourt Brace.
2. Brietzke, E,Vazquez, GH,Kang, MJ(2019).Pharmacological treatment for insomnia in patients with major depressive disorder.Expert Opin Pharmacother,20,1341-1349.
3. Buysse, DJ,Reynolds, CF, 3rd,Monk, TH(1989).The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research.Psychiatry Res,28,193-213.
4. Chen, KC,Yang, YK,Howes, O(2013).Striatal dopamine transporter availability in drug-naive patients with schizophrenia: a case-control SPECT study with [(99m)Tc]-TRODAT-1 and a meta-analysis.Schizophr Bull,39,378-386.
5. Fava, M(2004).Daytime sleepiness and insomnia as correlates of depression.J Clin Psychiatry,65(Suppl 16),27-32.
6. Gelenberg, AJ(2010).A review of the current guidelines for depression treatment.J Clin Psychiatry,71,e15.
7. Hayashino, Y,Yamazaki, S,Takegami, M(2010).Association between number of comorbid conditions, depression, and sleep quality using the Pittsburgh sleep quality index: results from a population-based survey.Sleep Med,11,366-371.
8. Hsieh, PC,Lee, IH,Yeh, TL(2010).Distribution volume ratio of serotonin and dopamine transporters in euthymic patients with a history of major depression – a dual-isotope SPECT study.Psychiatry Res,184,157-161.
9. Kuo, CC,Chien, IC,Lin, CH(2011).Prevalence, correlates, and disease patterns of antidepressant use in Taiwan.Compr Psychiatry,52,662-669.
10. Lai, IC,Wang, MT,Wu, BJ,Wu, HH,Lian, PW(2011).The use of benzodiazepine monotherapy for major depression before and after implementation of guidelines for benzodiazepine use.J Clin Pharm Ther,36,577-584.
11. Lam, RW,Kennedy, SH,Grigoriadis, S(2009).Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.J Affect Disord,117(Suppl 1),S26-S43.
12. Lee, LT,Tsai, HC,Chi, MH(2015).Lower availability of striatal dopamine transporter in generalized anxiety disorder: A preliminary two-ligand SPECT study.Int Clin Psychopharmacol,30,175-178.
13. Leu, SH,Chou, JY,Lee, PC(2015).Validity and reliability of the Chinese version of the Sheehan Disability Scale (SDS-C).Asia Pac Psychiatry,7,215-222.
14. Li, SX,Lam, SP,Chan, JW(2012).Residual sleep disturbances in patients remitted from major depressive disorder: a 4-year naturalistic follow-up study.Sleep,35,1153-1161.
15. McClintock, SM,Husain, MM,Wisniewski, SR(2011).Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication.J Clin Psychopharmacol,31,180-186.
16. Mendlewicz, J(2009).Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders.World J Biol Psychiatry,10,269-275.
17. Menza, M,Marin, H,Opper, RS(2003).Residual symptoms in depression: can treatment be symptom-specific?.J Clin Psychiatry,64,516-523.
18. Möller, HJ(2008).Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment.World J Biol Psychiatry,9,102-114.
19. National Collaborating Centre for Mental Health(ed.),National Institute for Health and Clinical Excellence(ed.)(2010).Depression: The Treatment and Management of Depression in Adults.Leicester, United Kingdom:British Psychological Society.
20. Novick, D,Montgomery, W,Moneta, V(2015).Antidepressant medication treatment patterns in Asian patients with major depressive disorder.Patient Prefer Adherence,9,421-428.
21. Nutt, D,Wilson, S,Paterson, L(2008).Sleep disorders as core symptoms of depression.Dialogues Clin Neuro Sci,10,329-336.
22. Paykel, ES(2008).Partial remission, residual symptoms, and relapse in depression.Dialogues Clin Neuro sci,10,431-437.
23. Riedel, M,Möller, HJ,Obermeier, M(2010).Response and remission criteria in major depression – a validation of current practice.J Psychiatr Res,44,1063-1068.
24. Rutherford, BR,Sneed, JR,Roose, SP(2009).Does study design influence outcome? the effects of placebo control and treatment duration in antidepressant trials.Psychother Psychosom,78,172-181.
25. Samples, H,Mojtabai, R(2015).Antidepressant self-discontinuation: results from the collaborative psychiatric epidemiology surveys.Psychiatr Serv,66,455-462.
26. Steiger, A,Dresler, M,Kluge, M(2013).Pathology of sleep, hormones and depression.Pharmacopsychiatry,46(Suppl 1),S30-S35.
27. van, Mill, JG,Hoogendijk, WJ,Vogelzangs, N(2010).Insomnia and sleep duration in a large cohort of patients with major depressive disorder and anxiety disorders.J Clin Psychiatry,71,239-246.
28. Woo, JM,Jeon, HJ,Noh, E(2014).Importance of remission and residual somatic symptoms in health-related quality of life among outpatients with major depressive disorder: a cross-sectional study.Health Qual Life Outcomes,12,188.
29. Wu, CH,Farley, JF,Gaynes, BN(2012).The association between antidepressant dosage titration and medication adherence among patients with depression.Depress Anxiety,29,506-514.
30. Wu, CS,Shau, WY,Chan, HY,Lai, MS(2013).Persistence of antidepressant treatment for depressive disorder in Taiwan.Gen Hosp Psychiatry,35,279-285.
31. Yao, G,Chung, CW,Yu, CF(2002).Development and verification of validity and reliability of the WHOQOL-BREF Taiwan version.J Formos Med Assoc,101,342-351.
32. Yeh, TL,Chen, KC,Lin, SH(2012).Availability of dopamine and serotonin transporters in opioid-dependent users – a two-isotope SPECT study.Psychopharmacology,220,55-64.
33. Zajecka, JM(2013).Residual symptoms and relapse: mood, cognitive symptoms, and sleep disturbances.J Clin Psychiatry,74(Suppl 2),9-13.